FDA Approves AbbVie's RINVOQ To Treat Active Psoriatic Arthritis
15/12 01:59
(RTTNews) - AbbVie (ABBV) said that the U.S. Food and Drug Administration has approved RINVOQ (upadacitinib; 15 mg, once daily) for the treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more tumor necrosis factor bloc...